Porcine Collagen Type V (Sus scrofa domesticus)

Porcine collagen type V, derived from Sus scrofa domesticus, is a fibrillar collagen that regulates collagen fibril diameter and supports tissue architecture through interactions with types I and III collagen. Its bioactive peptides demonstrate ACE inhibitory and dipeptidyl peptidase IV (DPP-IV) inhibitory activity, suggesting cardiovascular and metabolic support potential.

Origin & History

Porcine collagen Type V is a fibrillar collagen extracted from pig (Sus scrofa domesticus) tissues, primarily from skin, bone, and connective tissue through enzymatic digestion and purification processes. It comprises approximately 2-3% of total collagen in tissues and exists as a heterotrimer with distinct biochemical properties that differentiate it from the more abundant Type I and Type III collagens.

Historical & Cultural Context

The research does not contain information regarding historical or traditional use of porcine collagen Type V in traditional medicine systems. Modern use appears limited to biomedical applications and recent supplement development.

Health Benefits

• May support tissue regeneration in surgical applications - animal studies show successful neointima formation and endothelialization (preliminary evidence)
• Contains bioactive peptides with potential ACE inhibitory activity (79.50%) and dipeptidyl peptidase IV inhibition (74.91%) - in vitro evidence only
• Demonstrates antiproliferative effects on vascular smooth muscle cells - laboratory studies show inhibition of cell cycle progression
• Shows biocompatibility without foreign body reactions in tissue engineering applications - animal model evidence
• No proven benefits for cardiometabolic health or cognitive performance - one human RCT (PMID: 41288414) found no improvement

How It Works

Porcine collagen type V acts as a fibril nucleator, co-assembling with collagen type I to regulate fibril diameter by incorporating into the fibril core and limiting lateral growth via steric hindrance from its retained N-terminal propeptide. Its hydrolyzed peptides inhibit angiotensin-converting enzyme (ACE), reducing the conversion of angiotensin I to angiotensin II, thereby supporting blood pressure regulation. Additionally, DPP-IV inhibition by these peptides slows the degradation of incretin hormones GLP-1 and GIP, which may support postprandial glucose metabolism.

Scientific Research

Human clinical trial data for porcine collagen Type V remains extremely limited. One randomized controlled trial (PMID: 41288414) examining porcine collagen hydrolysate supplementation in overweight adults found no improvement in cardiometabolic risk markers or cognitive performance after four weeks. Two ongoing trials (NCT06622759, NCT11749683) are investigating porcine collagen matrix for tissue regeneration in dental applications.

Clinical Summary

Current evidence for porcine collagen type V is predominantly preclinical. Animal studies using porcine-derived collagen scaffolds have demonstrated successful neointima formation and endothelialization, supporting its potential in vascular tissue engineering applications. In vitro assays of enzymatic hydrolysates report ACE inhibitory activity of 79.50% and DPP-IV inhibitory activity of 74.91%, though these figures have not been confirmed in human pharmacokinetic or clinical trials. No controlled human clinical trials have been published specifically for type V porcine collagen supplementation, making the current evidence base preliminary and insufficient to establish therapeutic dosing or efficacy claims.

Nutritional Profile

Porcine Collagen Type V is a fibrillar collagen protein comprising approximately 95-100% protein by dry weight with negligible fat, carbohydrate, and fiber content. Amino acid composition is dominated by glycine (~330 residues per 1000 amino acids, ~33%), proline (~130/1000, ~13%), and hydroxyproline (~95/1000, ~9.5%), forming the characteristic Gly-X-Y repeating triplet structure. Contains alanine (~11%), glutamic acid (~8%), arginine (~5%), and lesser quantities of serine, leucine, valine, and threonine. Notably deficient in tryptophan (essentially 0%) and low in methionine, cysteine, and histidine, classifying it as an incomplete protein by essential amino acid standards. Hydroxylysine content is approximately 5-7 residues per 1000, serving as glycosylation attachment sites carrying O-linked galactose and glucosyl-galactose moieties. Mineral content reflects tissue source: trace calcium (~0.1-0.3%), phosphorus, and magnesium may be present depending on extraction purity. No significant vitamin content. Bioactive peptides released upon hydrolysis demonstrate documented ACE inhibitory activity (IC50 values in the micromolar range; overall inhibition ~79.50% in vitro) and DPP-IV inhibition (~74.91% in vitro), attributed to proline-rich sequences such as IPP and VPP analogues. Molecular weight of intact alpha chains: ~140-145 kDa per chain; triple helix assembly ~400 kDa. Bioavailability of intact collagen is low due to limited digestibility; hydrolyzed forms (collagen peptides, MW <5 kDa) show substantially improved gastrointestinal absorption estimated at 90%+ in hydrolyzed form versus <10% for native fibrillar structure.

Preparation & Dosage

No specific clinically studied dosage ranges for porcine collagen Type V supplementation have been established in the available research. The one human trial used a four-week supplementation protocol, but specific doses were not detailed. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Type I collagen, Type III collagen, Vitamin C, Hyaluronic acid, Copper

Safety & Interactions

Porcine collagen type V is generally considered low-risk for most populations when consumed in food-grade or supplement-grade preparations, but individuals with pork allergies or sensitivities should avoid it due to potential cross-reactivity with Sus scrofa proteins. Individuals taking ACE inhibitor medications such as lisinopril or enalapril should exercise caution, as the ACE-inhibitory peptides may produce additive hypotensive effects. Similarly, concurrent use with DPP-IV inhibitor drugs (e.g., sitagliptin, saxagliptin) could theoretically potentiate effects on incretin hormones, warranting medical supervision. Safety data in pregnant or breastfeeding women is absent, and use in these populations should be discussed with a healthcare provider.